Publications by authors named "Bruce S Schneider"
The U.S. Food and Drug Administration applies regulatory flexibility to balance benefits and risks to subjects in cell-therapy clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to investigate the occurrence of hyperglycemia in patients taking quetiapine, an atypical antipsychotic medication.
- Out of 46 reports of hyperglycemia linked to quetiapine, 34 involved new cases, while some patients had worsened existing diabetes; the age of affected individuals ranged from 5 to 76 years.
- The findings suggest that quetiapine may unmask or lead to hyperglycemic conditions, with serious complications reported, including 21 cases of diabetic ketoacidosis and 11 fatalities identified by a retrospective survey.
Study Objective: To explore the clinical characteristics of hyperglycemia in patients treated with risperidone.
Design: Pharmacovigilance survey of spontaneously reported adverse events in risperidone-treated patients, with reports of haloperidol-associated hyperglycemia used as a control.
Setting: Government-affiliated drug evaluation center.
Objective: To provide insight into discussions at the Surgeon General's Listening Session, "Toward a National Action Plan on Overweight and Obesity," and to complement The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity.
Research Methods And Procedures: On December 7 and 8, 2000, representatives from federal, state, academic, and private sectors attended the Surgeon General's Listening Session and were given an opportunity to recommend what to include in a national plan to address overweight and obesity. The public was invited to comment during a corresponding public comment period.